People
Our laboratory offers a dynamic research environment. We are constantly looking for motivated scientists and students to join our team. For available open positions contact Päivi M. Ojala.
Päivi M. Ojala

Principal Investigator

To discover novel mechanisms of cancer development and progression, our group is studying the virus-host interactions involved in pathogenesis of Kaposi Sarcoma herpesvirus (KSHV), an oncogenic gamma-2 herpesvirus. KSHV can infect both blood and lymphatic endothelial cells (BECs and LECs, respectively), inducing a virus-specific de-differentiation program which contributes to KS tumorigenesis.  Furthermore, the outcome of the infection is different in the two cell types. While in BECs KSHV establishes a latent infection with very few viral proteins expressed, in LECs, the virus displays a dysregulated/lytic expression program with spontaneous production of infectious virus. To identify new therapeutic approaches for the KSHV-associated cancers the research in the group also focuses to identify novel signaling pathways and cellular proteins critical for KSHV viral replication by functional genomics and automated high-content imaging approaches.

We are also interested in understanding the molecular circuits contributing to cancer cell metastasis, with a special focus on cancers disseminating through the lymphatic system. To this end we are investigating the interactions of cancer cells with the LECs using several co-culture cell models to mimic the cancer cell-LEC interactions in vivo.

Paivi.Ojala@helsinki.fi

Nadezhda Zinovkina

Laboratory Manager and research assistant

I participate in the scientific projects by providing help in various laboratory techniques for cell biology (cell culture, lentivirus, retrovirus and KSHV preparation), molecular biology (cloning, PCR, western blotting, immunostaining and fluorescent microscopy), microbiology, pathology (mouse tissue processing, paraffin embedding and sectioning).

Nadezhda.Zinovkina@helsinki.fi

Hector Monzo

Postdoctoral Researcher

Chimeric Antigen Receptor (CAR) T cell adoptive cell therapy has revolutionized cancer treatment with a remarkable efficacy in the treatment of B-lineage acute lymphoblastic leukemia and lymphomas in adults and children. In CAR T therapy, patient-derived T cells are isolated in the lab and genetically manipulated via viral transduction to express a CAR against a specific tumor-associated antigen (TAA). CAR T cells are then infused back into the patient and mount a tumor-directed immune response upon TAA interaction. The CAR confers both target cell recognition as well as activation of the effector T cell, thus equipping the body’s own immune system to fight effectively cancer.

Despite its efficacy in hematological malignancies, CAR T therapies have had hitherto little success in treating solid tumors. The challenges for CAR T cells against solid malignancies are associated with three key tumor features, (i) TAA heterogeneity, (ii) tumor microenvironment and, (iii) immunosuppression.

With the support of The Cancer Foundation Finland (Syöpäjärjestöt) our research aims to engineer a CAR with improved homing, trafficking and targeting against solid tumors.

Sanni Alve

PhD Student

My project focuses on melanoma cell crosstalk with lymphatic endothelial cells (LECs). We have demonstrated that melanoma cell communication with LECs actively promotes invasion and metastasis of melanoma cells. Currently, I am studying the prometastatic functional and molecular changes  in both cell types upon this crosstalk. 

sanni.alve@helsinki.fi

Krista Tuohinto

PhD Student

To understand the cell tropism of KSHV for lymphatic endothelial cells forms the core of my project. My research focuses on the interaction of lymphatic transcription factors, Prox1 and Sox18, with various host epigenetic remodelers that regulate KSHV latent and lytic replication. This will help to elucidate the mechanisms governing the KSHV lytic and latent replication in lymphatic endothelial cells. Also, by utilizing endothelial precursor cells isolated from the blood of healthy individuals, I am developing a new KSHV-infection model for testing inhibitors of the KSHV replication in collaboration with a biotechnology company.

krista.tuohinto@helsinki.fi

Joonas Jukonen

PhD Student

I performed the first part of my PhD thesis project by studying the role of the Eph-ephrin signaling pathway in high-grade serous ovarian cancer. I am currently focusing on the transcription factor SOX18. The aim of my current project is to elucidate the mechanics and functions of SOX18 signaling in gastric and ovarian cancers. 

Kerttu Kalander

PhD Student

I am researching CAR T cell therapy with a focus on solid tumor treatment. The aim is to improve CAR T cells to have a better capability of reaching their target cancer cells and sustaining effector functions in the stroma rich and immunosuppressive environment.

Lab Alumni
  • Annika Järviluoma
  • Susanna Räsänen
  • Evita Elfving
  • Grzegorz Sarek
  • Christel Pussinen
  • Sonja Koopal
  • Johanna Furuhjelm
  • Sari Tynkkynen
  • Anne Aarnio
  • Fang Cheng
  • Anne Lehtonen
  • Simonas Laurinavicius
  • Liisa Lappalainen
  • Jaakko Lehtimäki
  • Li Ma
  • Nina Perälä
  • Jenni Vaaksio
  • Elisa Kaivanto
  • Markus Vähä-Koskela
  • Jenny Bärlund
  • Veronika Rezov
  • Otso Niiranen
  • Johanna Viiliäinen
  • Adewale Taiwo
  • Pirita Pekkonen
  • Giuseppe Balistreri
  • Sudar Krishnam Rajan Shanthi
  • Raquel Díaz Martínez
  • Tomasz Benedyk
  • Francesca Falasco
  • Micaela Haapanen
  • Heidi Jutila
  • Veijo Nurminen
  • Endrit Elbasani
  • Silvia Gramolelli